Inhibition of Influenza Virus Replication by Constrained Peptides Targeting Nucleoprotein

Jiang, Hongbing; Xu, Yuelong; Li, Li; Weng, Leiyun; Wang, Qiang; Zhang, Shijian; Jia, Baosen; Hu, Hongxing; He, Ying; Jacob, Yves; Toyoda, Tetsuya

doi:10.3851/imp1902

Cited by 12 publications

(16 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiviral peptide therapeutics has the potential in combating viral infections [30], [31]. Particularly during the past decade there has been a considerable focus on HIV therapy and a lot of peptides have been tested against this pathogen.…”

Section: Discussionmentioning

confidence: 99%

HIPdb: A Database of Experimentally Validated HIV Inhibiting Peptides

2013

View full text Add to dashboard Cite

BackgroundBesides antiretroviral drugs, peptides have also demonstrated potential to inhibit the Human immunodeficiency virus (HIV). For example, T20 has been discovered to effectively block the HIV entry and was approved by the FDA as a novel anti-HIV peptide (AHP). We have collated all experimental information on AHPs at a single platform.DescriptionsHIPdb is a manually curated database of experimentally verified HIV inhibiting peptides targeting various steps or proteins involved in the life cycle of HIV e.g. fusion, integration, reverse transcription etc. This database provides experimental information of 981 peptides. These are of varying length obtained from natural as well as synthetic sources and tested on different cell lines. Important fields included are peptide sequence, length, source, target, cell line, inhibition/IC50, assay and reference. The database provides user friendly browse, search, sort and filter options. It also contains useful services like BLAST and ‘Map’ for alignment with user provided sequences. In addition, predicted structure and physicochemical properties of the peptides are also included.ConclusionHIPdb database is freely available at http://crdd.osdd.net/servers/hipdb. Comprehensive information of this database will be helpful in selecting/designing effective anti-HIV peptides. Thus it may prove a useful resource to researchers for peptide based therapeutics development.

show abstract

Section: Discussionmentioning

confidence: 99%

HIPdb: A Database of Experimentally Validated HIV Inhibiting Peptides

2013

View full text Add to dashboard Cite

show abstract

“…Apart from existing drugs and vaccines, there is a need to explore new antiviral candidates to control pathogenic re-emerging and resistant viruses (2). Antiviral peptides (AVPs) are a potential alternative strategy in this context (3). …”

Section: Introductionmentioning

confidence: 99%

AVPpred: collection and prediction of highly effective antiviral peptides

Thakur

Qureshi

Kumar

2012

Nucleic Acids Research

254

247

View full text Add to dashboard Cite

In the battle against viruses, antiviral peptides (AVPs) had demonstrated the immense potential. Presently, more than 15 peptide-based drugs are in various stages of clinical trials. Emerging and re-emerging viruses further emphasize the efforts to accelerate antiviral drug discovery efforts. Despite, huge importance of the field, no dedicated AVP resource is available. In the present study, we have collected 1245 peptides which were experimentally checked for antiviral activity targeting important human viruses like influenza, HIV, HCV and SARS, etc. After removing redundant peptides, 1056 peptides were divided into 951 training and 105 validation data sets. We have exploited various peptides sequence features, i.e. motifs and alignment followed by amino acid composition and physicochemical properties during 5-fold cross validation using Support Vector Machine. Physiochemical properties-based model achieved maximum 85% accuracy and 0.70 Matthew’s Correlation Coefficient (MCC). Performance of this model on the experimental validation data set showed 86% accuracy and 0.71 MCC which is far better than the general antimicrobial peptides prediction methods. Therefore, AVPpred—the first web server for predicting the highly effective AVPs would certainly be helpful to researchers working on peptide-based antiviral development. The web server is freely available at http://crdd.osdd.net/servers/avppred.

show abstract

“…A peptide encompassing NP tail domain residues 402-428 inhibits oligomerization and replication [60]. Another proline-rich constrained peptide was shown to bind to NP and inhibit influenza replicons [141]. In silico screening of virtual libraries for docking to CTL epitope sites within NP identified 3-mercapto-1,2,4-triazole derivatives that inhibited virus replication [142].…”

Section: Other Influenza Virus Np Inhibitorsmentioning

confidence: 99%

Influenza Nucleoprotein: Promising Target for Antiviral Chemotherapy

Cianci

Gerritz

Deminie

et al. 2013

Antivir Chem Chemother

View full text Add to dashboard Cite

In the search for new anti-influenza agents, the viral polymerase has often been targeted due to the involvement of multiple conserved proteins and their distinct activities. Polymerase associates with each of the eight singled-stranded negative-sense viral RNA segments. These transcriptionally competent segments are coated with multiple copies of nucleoprotein (NP) to form the ribonucleoprotein. NP is an abundant essential protein, possessing operative and structural functions, and participating in genome organization, nuclear trafficking and RNA transcription and replication. This review examines the NP structure and function, and explores NP as an emerging target for anti-influenza drug development, focusing on recently discovered aryl piperazine amide inhibitor chemotypes.

show abstract

Inhibition of Influenza Virus Replication by Constrained Peptides Targeting Nucleoprotein

Cited by 12 publications

References 47 publications

HIPdb: A Database of Experimentally Validated HIV Inhibiting Peptides

HIPdb: A Database of Experimentally Validated HIV Inhibiting Peptides

AVPpred: collection and prediction of highly effective antiviral peptides

Influenza Nucleoprotein: Promising Target for Antiviral Chemotherapy

Contact Info

Product

Resources

About